Virotoxicity of Oligodynamic Silver
Viruses cause most upper respiratory tract infections (URTIs), such as adenovirus, coronavirus, coxsackievirus, influenza virus, parainfluenza virus, respiratory syncytial virus, and rhinovirus, which account for the majority of cases. (1) A broad-spectrum anti-viral agent that really works is needed to combat over 200 viruses that cause URTIs. (2) Undoubtedly oligodynamic silver fits this bill.
Emerging medical studies confirm the stellar, broad-spectrum virotoxic efficacy of oligodynamic silver both in vitro and in vivo. This includes some of the most formidable viral organisms like HIV (including co-infections) (3-11) and Herpesvirus hominis (HSV). (12-18) Despite the low yields of oligodynamic silver of the past 100 years common to silver-based drugs, the collective authoritative medical literature has documented efficacy of silver's virotoxicity against over 24 viruses. For the viruses relevant to URTIs, the following are known to succumb to oligodynamic silver:
Coxsackie virus type B-3 (CB-3); (21)
Influenzae (strains not identified); (22-24)
Influenza A; (25,26)
Influenza B (Haemophilus influenzae); (27)
Rhinovirus type 1A; (28) and
HSV-(URTI), as referenced above.
Bactericidal Properties of Oligodynamic Silver in URTI
Oligodynamic silver's antimicrobial efficacy extends well beyond its virotoxicity. Oligodynamic silver's lethal effects span across all microbial domains (viral, bacterial, and fungal). The following URTI-related bacteria are known to be susceptible to oligodynamic silver:
Beta hemolytic streptococci, (29-38) which causes tonsillopharyngeal cellulitis, tonsillopharyngeal abscess (39) (including reduced nasopharangeal abscesses), (40) otitis media, (41-43) plus sinusitis, (44-46) and up to ten percent of cases of adult pharyngitis (47) and the associated condition, and scarlet fever; (48)
Bordetella pertussis; (73,74) (causes less than 10% of acute tracheobronchitis cases); Spring Catarrh (obsolete nomenclature); (83) and Pneumococci (84)/Pneumonia; (85) And finally, inflammatory conditions of the eyes, ears, nose, and throat. (77-82)
Streptococcus pneumoniae; (49) Corynebacterium diphtheriae; (50-53) Neisseria gonorrhoeae; (54-60) Herpesvirus hominis (HSV); (61-68) Klebsiella pneumoniae; (69-71) Haemophilus influenzae; (72) Mycobacterium (Tuberculosis); (75,76)
Perhaps oligodynamic silver's most compelling nature lies in its ability to successfully eradicate pervasive primary and secondary co-infections simultaneously. A major, double-blind, controlled trial concerning advanced AIDS candidiasis and immunity-suppressing moieties demonstrated complete sero-negative conversion after a single treatment with oligodynamic silver hydrosol! The studies were conducted at Lucha Contra el Sida, Comayaguela, Tegucigalpa, Honduras, Central America.
Quoting from the study, "Furthermore, said devices [silver oxide hydrosol] are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV), so as to restore the immune system." (86) (Brackets added by authors.)
This single treatment delivered a total of 200 mg of silver for a 70 kilogram patient, well within the lowest observed adverse event level (LOAEL) established by the EPA for injected silver. (87) Unlike picoscalar oligodynamic silver hydrosol devoid of silver oxide, the former required activation into an oligodynamic state with persulfate. Nevertheless, the results were astounding.
Pharmacokinetics is concerned with how the body affects the Absorption, Distribution, Metabolism, and Excretion (ADME) of the silver-based drug:
(1) Time course of Absorption: The absorption of picoscalar silver hydrosol is nearly...
This is a preview. Get the full text through your school or public library.